Online inquiry

IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5640MR)

This product GTTS-WQ5640MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5640MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15567MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ6157MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ6686MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ2125MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ7227MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1539MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ8759MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ12429MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW